Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRiME: PEP-CMV in Recurrent Medulloblastoma and Malignant Glioma
NCT03299309Phase 1Active, not recruiting
- Start
- Jun 2018
- Primary completion
- Apr 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PEP-CMV in medulloblastoma and malignant glioma. Primary endpoint: Proportion of patients with unacceptable toxicity. Started Jun 2018; status: active, not recruiting.
02
Drugs
PEP-CMV
03
Conditions
medulloblastomamalignant glioma
Beyond the preview
Go deeper on NCT03299309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299309.